Meningioma

Senolytic plus senogenic combinations demonstrate robust preclinical efficacy in reducing tumor growth and senescent burden while promoting apoptosis across diverse in vivo models. These findings highlight senotherapy as a promising adjunct to conventional senescence-inducing anticancer therapies and underscore the need for standardized in vivo methodologies and translational studies to guide clinical application. This review protocol was prospectively registered on PROSPERO (registration number: CRD420251161998).

P=N/A, N=140, Not yet recruiting, The first affiliated hostipal of nanchang university; The first affiliated hostipal of nanchang university

Schwannomas exhibit minimal [Ga68]DOTATATE avidity, in contrast to SSTR2-expressing tumors such as meningiomas. [Ga68]DOTATATE PET may therefore aid in non-invasively differentiating schwannomas from SSTR2-expressing tumors with overlapping MRI features in diagnostically challenging cases.

P=N/A, N=238, Not yet recruiting, Centre Hospitalier St Anne

Considering the availability of PPAR modulatory drugs, it may be an important therapeutic target. In addition, the meticulous examination of the brain invasion still holds significant promise for prognostication.

Particular emphasis is placed on advances in dosimetry, quantitative imaging, and radiomics, which are beginning to refine patient selection and improve response prediction. Together, current evidence highlights the therapeutic potential of radionuclide therapy in aggressive or refractory meningiomas and underscores the need for further prospective trials to define its optimal clinical application.

Although based on heterogeneous and limited data, intra-arterial RLT appears to be a promising therapeutic strategy for recurrent brain tumors. Future research should focus on improving radioligand delivery beyond the blood-brain barrier and enhancing effective tumor targeting.

Constitutional CHEK2 mutations combined with somatic NF1 defect may have promoted the malignant progression of SEGA-imitating fibrous meningioma and its favorable initial response to mTOR inhibitors.

P2, N=40, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Dec 2025 --> Jun 2026

P2, N=0, Withdrawn, University of Nebraska | N=27 --> 0 | Suspended --> Withdrawn | Trial primary completion date: Apr 2026 --> Apr 2027

The findings reveal that the infiltration of CD163+ macrophages in meningioma may be mediated by the IL-17/CSF1 axis through SMARCB1 regulation.

Efficacy of Decitabine (DCT) - a chemical analogue of AZA - was demonstrated in a subset of primary meningioma cells. Molecular impact was largely independent of DNMT expression and methylation profile. Next to inducing DNA demethylation and epigenetic reprogramming, efficacy of AZA may be due to other molecular mechanisms of action.